Resistant gram-negative infections in a pediatric intensive care unit: a retrospective study in a tertiary care center

Bir üniversite hastanesi çocuk yoğun bakım biriminde dirençli gram-negatif enfeksiyonların değerlendirilmesi

Abstract

Aim: Healthcare-associated infections cause increased morbidity and mortality in intensive care units. In this study, it was aimed to compare infections with multi-drug resistance and extended drug resistance, while evaluating the characteristics of resistant Gram-negative infections in the pediatric intensive care unit in our university hospital.

Material and Methods: In this study, pediatric patients who were found to have Gram-negative infections during hospitalization in the pediatric intensive care unit in our faculty between January 2011 and December 2015, were evaluated retrospectively.

Results: One thousand thirty patients were internalized in our unit in the study period. The incidence for healthcare-associated infection was found as 17.2% and the incidence density of hospitalization in our unit was 22.05. The rate for device use was calculated as 66.9 per 1000 patient days. The incidence for healthcare-related infection per 1000 device days and the rate for device use were calculated as 66.9 and 0.59, respectively. One hundred thirty Gram-negative infection episodes were found in 79 patients whose median age was 22 (1–205) months. The most common infections included ventilator-related pneumonia (n=78, 60%) and bloodstream infections (n=38, 29.2%). The most common causative agents included Pseudomonas aeruginosa (n=50, 38.5%), Klebsiella pneumonia (n=32, 24.6%) and Acinetobacter baumannii (n=28, 21.5%). Among A. baumannii isolates, the rates for resistance against piperacillin-tazobactam and meropenem were found as 96.4% and 89.3%, respectively. Empirical use of carbapenems, aminoglycosides, and fluoroquinolones, the presence of total parenteral nutrition and history of Gram-negative bacterial infections prior to pediatric intensive care unit admission were significantly more common among extended-drug Gram-negative bacterial infections. The late mortality rate was found to be higher in presence of extended drug resistance.

Corresponding Author / Sorumlu Yazar: Gürkan Atay  
E-mail / E-posta: drgurkanatay@yahoo.com

Cite this article as: Atay G, Kara M, Sütçü M, et al. Resistant gram-negative infections in a pediatric intensive care unit: a retrospective study in a tertiary care center. Turk Pediatri Ars 2019; 54(2): 105–12.
Introduction

Healthcare-associated infections (HAIs) lead to increased morbidity and mortality in intensive care units (ICUs) (1). Many factors including frequent contact with healthcare workers, long-term hospitalization in ICUs, frequent invasive procedures, and the presence of comorbidities increase the risk of HAIs, especially including cases caused by resistant causative agents (2). Despite an increase in resistant nosocomial infections, studies in the area of new antibiotic development are not sufficient (3). In addition, studies reporting the pharmacokinetic characteristics and reliability of newly developed antibacterial agents in children are considerably limited. Therefore, management of resistant infections is especially difficult in pediatric intensive care units (PICU).

Generally, more than one-third of HAIs are caused by Gram-negative microorganisms including mainly multidrug-resistant (MDR) agents (4). This frequency reaches 70% in ICUs (5). The United States of America (USA) Centers for Disease Control and Prevention (CDC) has called attention to the marked increase in imipenem and fluoroquinolone-resistant *P. aeruginosa*, carbapenem-resistant *A. baumannii*, and third-generation cephalosporin and carbapenem-resistant Enterobacteriaceae species (4). One of the most important reasons for this is undoubtedly inappropriate antibiotic use. For antibiotics to be used efficiently for adequate time periods, physicians should know of the antibacterial resistances in their own units. Although there are studies related to adult ICUs in this area, data involving PICUs are limited.

In this study, it was aimed to evaluate the clinical and laboratory characteristics of resistant Gram-negative infections (GNI), antibiotic resistances, and treatment responses in the pediatric ICU in our university hospital, and to compare GNIs that had multi-drug resistance and extended drug resistance.

Material and Methods

**Pediatric intensive care unit and active surveillance**

Pediatric patients who were found to have resistant GNI during hospitalization in the PICU in a tertiary care university hospital between January 2011 and December 2015 were included in this study. In the study period, 1030 patients were hospitalized in the PICU; the incidence of HAIs was found as 17.2% and the incidence density was found as 32.7 per 1000 patient days. One hundred thirty GNI episodes were found in 79 patients (female=30, 38%) whose median age was 22 (1–205) months (Table 1). Two GNI episodes were found in 43 (54.4%) patients and 3 GNI episodes were found in 4 patients (5.1%). The HAI incidence per thousand material days and the rate of material use were found as 66.9 and 0.59, respectively.

| Table 1. The patients’ clinical characteristics |
|-----------------------------------------------|
| n   | %   |
| Total number of patients                      | 79  |
| Age (months), median (range)                  | 22  (1–125) |
| Sex                                          |     |
| Female                                       | 30  | 38 |
| Male                                         | 49  | 62 |
| Underlying disease                           |     |
| Neurologic disease                           | 22  | 27.8 |
| Metabolic disease                            | 13  | 16.4 |
| Chronic liver disease                        | 7   | 8.9 |
| Chronic heart disease                        | 5   | 6.3 |
| Malignancy                                   | 3   | 3.8 |
| Chronic lung disease                         | 3   | 3.8 |
| Primary immunodeficiency                     | 2   | 2.5 |
| Chronic renal failure                        | 2   | 2.5 |
| Diabetes mellitus                            | 1   | 1.3 |
| Hospitalization time in PICU (days), median (range) | 35 (3–201) |
| PRISM score during hospitalization in PICU, median (range) | 9 (2–40) |
| Early mortality rate                         | 9   | 11.3 |
| Late mortality rate                          | 21  | 26.6 |

**PICU:** Pediatric intensive care unit; **PRISM:** Pediatric risk of mortality score
The PICU in our clinic includes six beds and gives service to complicated patients aged between 1 month and 18 years. There are two rooms each including three beds. There is no isolation room in our unit. The patient-nurse ratio is 2:1.

Since January 2010, active surveillance has been conducted in our PICU by a nurse and a specialist of pediatric infectious diseases who are employed by the Hospital Infection Control Committee (HICC). In this context, HAIs are regularly recorded and reported to the HICC monthly.

In our unit, the primary approach is to initiate treatment with anti-pseudomonal penicillin or cephalosporin when a GNI is suspected. If culture remains negative after the first 48–72 hours, aminoglycoside is added to treatment or carbenepem treatment is initiated. Empirical fluoroquinolon, colistine or combination treatment are not preferred unless the patient carries high risk in terms of resistant GNI. During initiation and adjustment of antibiotic treatment, the resistance status specified with surveillance in our unit, the presence of agent with extended drug resistance (EDR) and the colonization status of the host are determinative.

Data collection
Data related to the patients [age, sex, underlying disease, hospitalization time before PICU, previous GNI, history of antibiotic and immunosuppressive drug use, Pediatric Mortality Risk Scoring (PRISM) during hospitalization in the PICU, presence of central venous catheter (CVC), presence of urinary catheter and total parenteral nutrition, and type and time of mechanical ventilation (MV) (intubation/tracheostomy)] were recorded retrospectively from patient files and the computer system by way of predetermined standard questionnaires.

Definitions
The diagnosis of HAI was made by a nurse and a specialist of pediatric infectious diseases who were employed by the HICC in the scope of active surveillance according to the HICC criteria (6).

Infections that developed 48 hours after hospitalization in the PICU, and had no manifestation at the time of hospitalization or in the incubation period, were considered as HAIs. The incidence of HAIs (%) was calculated using the formula "(HAI number/number of hospitalized patients) x 100" and the HAI incidence density was calculated using the formula "(HAI number/patient days) x 1000". The incidence density was defined as "(HAI episode number/patient days) x 1000". The total patient days and the number of days when materials including central venous catheter, endotracheal tube, and urinary catheter were used, were recorded. The HAI incidence per material use day and the material usage rate were calculated using the formulas "(HAI episode number/material usage days) x1000" and “total material usage days/total patient days),” respectively.

The presence of resistance to one agent in at least 3 antimicrobial categories each was defined as ‘MDR,’ and the presence of sensitivity to antibacterial agents in one or two categories was considered ‘EDR.’

Use of systemic antibiotics for 72 hours or longer in 30 days prior onset of infections was expressed as ‘prior antibiotic use.’ Mortality in the first 7 days after the infection episode was recorded as ‘early mortality rate’ and mortality arising from any reason in 30 days was recorded as ‘late mortality rate.’

Laboratory data
Complete blood count, transaminase levels, renal function tests, C-reactive protein (CRP), and procalcitonin (PCT) concentrations, and complete urinalysis, which were routinely ordered during the follow-up of the patients, were recorded. Microbiologic culture results and antibiogram sensitivities for blood obtained from catheters or peripheral blood, for tracheal aspirate obtained from endotracheal tubes or tracheostomy cannulae in patients on MV and for urine and other body fluids, were recorded.

Microbiologic examination
Samples of respiratory tract and sterile body fluids were primarily examined using Gram staining. The tracheal aspirate samples were cultured in 5% sheep blood agar (Becton Dickinson, Germany) and chocolate agar (Oxoid, England) and incubated for 24–48 hours in a 5% CO₂ setting. When they were cultured in Mac Conkey agar (Oxoid, England), they were incubated for 24–48 hours at normal atmospheric conditions. Blood cultures were studied using a BACTEC 9120 (Becton Dickinson, USA) system. When a positive signal in favour of growth was obtained, they were cultured in 5% sheep blood agar and chocolate agar.

Urine samples were inoculated in chromogenic agar (BD CHROMagar Orientation Medium, Germany) and incubated for 24–48 hours at normal atmospheric conditions. Sterile body fluids were inoculated in 5% sheep blood agar, Schaedler agar (Oxoid, England), and meat broth (Oxoid, England) and anaerobic conditions were provided by way of a GasPak system (Becton Dickinson, USA).
The pathogens that were isolated were defined by way of traditional methods (Gram staining, catalase, oxidase, DNase, use of carbohydrate, urease, use of citrate, lysine decarboxilase, Voges-Proskauer, movement, and indol tests). Antimicrobial sensitivity tests were performed in Mueller Hinton agar (Oxoid, England) using the Kirby Bauer disc method in accordance with the recommendations of the Clinical Laboratory Standards Institute (CLSI). Appropriate antibiotic discs were used for Enterobacteriaceae, Gram-negative rods (BD BBL, Sensi-Disc, USA).

The gradient test (E test, bioMérieux, France) was studied for minimal inhibitor concentration and the results were evaluated according to the CLSI criteria (7).

**Statistical analysis**
Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS Inc; Chicago, IL, USA) Version 21 package program. Normality was tested using the Shapiro-Wilk and Kolmogorov-Smirnov tests. Data are expressed as median, minimum-maximum, frequency and percentage. Measuremental data that did not show normal distribution were compared using the Mann-Whitney U test in independent groups. Categorical data were evaluated using the Chi-square and Fisher’s exact test. The significance limit was set at p<0.05.

Ethics committee approval was obtained from Istanbul Medical Faculty Ethics Committee for this study (2017/485). Patient consent was not obtained because this study, which was adjusted in accordance with the Helsinki principles, was conducted retrospectively.

**Results**
The demographic and clinical characteristics of the patients are shown in Table 1. One hundred thirty GNI episodes were found in 79 patients (female=30, 38%) whose median age was found as 22 (range, 1–205) months. Two GNI episodes were found in 43 patients (54.4%) and 3 GNI episodes were found in 4 patients (5.1%). The incidence of HAIs was found as 17.2% and the incidence density was 32.7 per 1000 patient days. The incidence of HAIs per 1000 material days and the rate of material use were found as 66.9 and 0.59, respectively.

Among a total of 130 GNI episodes, 45.3% (n=59) were MDR infections and 27.6% (n=3) were EDR infections. The patients’ median hospitalization time in the PICU was found as 35 (range, 3–201) days. An underlying chronic disease was present in 58 (78.4%) patients. No significant difference was found when the presence of primary disease was compared in terms of GNI resistance (MDR/EDR).

The most common GNIs were found to be ventilator-associated pneumonia (VAP) (n=78, 60%) and blood-stream infections (BSI) (n=38, 29.2%). Catheter-associated infection (CAI) (n=9, 6.9%) and urinary tract infection (UTI) (n=4, 3.1%) were found less commonly. Peritonitis was found in one patient. The distribution of GNIs by culture specimens is shown in Table 2.

No GNIs were found that were resistant to all drugs. No significant difference could be found between MDR and EDR GNIs in terms of laboratory criteria (Table 2).

The distribution of the microorganisms by culture specimens is shown in Table 3 and their antibacterial resistances are shown in Table 4.

Various combination treatments including mainly meropenem+amikacin (n=25, 19.2%) were used during treatment of Gram-negative infections in 73.1% of the cases (Table 1).

When the characteristics of MDR and EDR GNIs were compared, the presence of hospitalization for more than 15 days before the PICU was found to be significantly more common and the median hospitalization time in the PICU was found to be significantly longer in EDR-GNIs (p=0.001 and p=0.005, respectively). The frequencies for empirical use of carbapenem, aminoglycoside, and fluoroquinolone, the presence of total parenteral nutrition, and history of GNI prior to the PICU were found to be significantly higher in EDR-GNIs (p=0.005, p=0.004, p=0.02, p=0.004, and p<0.001, respectively). A higher rate of EDR was found in A. baumannii species (p<0.001) in contrast to P. aeruginosa (p=0.01). There was no difference between the groups in terms of early mortality, but late mortality was found to be higher in EDR-GNIs (p=0.022).

In the comparison of the categorical data, the variables that were found to be statistically significant (p<0.05) were evaluated with logistic regression analysis. Past history of GNI, a hospitalization period of >15 days prior to the PICU, and growth of A. baumannii were found to be independent risk factors in terms of EDR-GNIs (Table 5).

Mortality was observed in 9 (11.3%) cases in 7 days after the development of an HAI. In these patients, the median age was found as 31 months and the median PRISM score was 12 (range, 4–40). Chronic disease was present in four patients; the most common HAI was VAP (n=5).

**Discussion**
Infections are the main reason of mortality in non-critical ICUs (1). In an international study, the prevalence
of ICU-associated HAI was found as 18.9% (2.3–49.2%), though there was a difference between regions (8). Similarly, the rate of HAIs was found as 51% in the EPIC II point prevalence study, which involved 1265 ICUs from 76 countries (9). Infection rates are higher in developing countries, including our country (1). In a multi-center study published recently by Leblebicioglu et al. (10), the rates of device-associated HAI in our country were found to be above the International Nosocomial Infection Control Consortium report and USA National Health Safety Network data. The frequency of HAIs was found as 17.2% in our study, in accordance with the literature.

### Table 2. Comparison of the clinical characteristics of resistant Gram-negative infections

| Variable (n) | DR-GNI | EDR-GNI | p   |
|--------------|--------|---------|-----|
|               | n      | %       | n   | %   |     |
| Total number of episodes | 59/130 (45.3) | 36/130 (27.7) |    |    | 0.001* |
| Hospitalization time prior to PICU >15 days | 34 | 57.6 | 32 | 88.9 | 0.001a |
| PRISM score during hospitalization in PICU, median (range) | 9 (2–21) | 7.5 (2–19) | 0.62c |
| Hospitalization time in PICU (days), median (range) | 38 (9–190) | 50.5 (3–201) | 0.005c |
| Use of antibiotic in the last 30 days | 58 | 98.3 | 36 | 100 | 0.62a |
| Empirical use of antibiotics |        |         |     |     |     |
| Carbapenem | 45 | 76.3 | 35 | 97.2 | 0.005b |
| Third-generation cephalosporin | 49 | 83.1 | 30 | 83.3 | 0.97a |
| Aminoglycoside | 48 | 81.4 | 36 | 100 | 0.004b |
| Anti-pseudomonal penicillin | 44 | 74.6 | 32 | 88.9 | 0.07a |
| Fluoroquinolone | 13 | 22 | 16 | 44.4 | 0.02a |
| Presence of invasive intervention |        |         |     |     |     |
| Intubation/MV | 59 | 100 | 35 | 97.2 | 0.37b |
| Central venous catheter | 59 | 100 | 36 | 100 |      |
| Total parenteral nutrition | 37 | 62.7 | 32 | 88.9 | 0.004b |
| Urinary catheterization | 54 | 91.5 | 35 | 97.2 | 0.25b |
| Tracheostomy | 21 | 35.6 | 15 | 41.7 | 0.55b |
| Surgical drain | 7 | 11.9 | 5 | 13.9 | 0.77b |
| Hemodialfiltration | 14 | 23.7 | 13 | 36.1 | 0.19b |
| PEG | 7 | 11.9 | 6 | 16.7 | 0.35b |
| Surgery | 22 | 37.3 | 19 | 52.8 | 0.21b |
| History of GNI prior to PICU | 26 | 44.1 | 30 | 83.3 | <0.001c |
| Laboratory measurements, median (range) |        |         |     |     |     |
| Number of white blood cells (cell/µL) | 12,310 (4250–26,800) | 1300 (3100–28,200) | 0.47c |
| Absolute neutrophil count (cell/µL) | 4300 (850–18,760) | 6450 (410–21,300) | 0.72c |
| C-reactive protein (mg/L) | 89 (24–421) | 128 (31–389) | 0.22c |
| Procalcitonin (μg/L) | 1.5 (0.15–4.1) | 1.6 (0.5–5.2) | 0.19c |
| MV time (days), median (range) | 19 (3–54) | 24.5 (3–83) | 0.056c |
| Microorganism |        |         |     |     |     |
| *P. aeruginosa* | 26 | 44.1 | 7 | 19.4 | 0.01a |
| *A. baumannii* | 6 | 10.2 | 22 | 61.1 | <0.001a |
| *K. pneumonia* | 17 | 28.8 | 6 | 16.7 | 0.18a |
| Early mortality rate | 4 | 6.7 | 5 | 13.9 | 0.25c |
| late mortality rate | 8 | 13.6 | 12 | 33.3 | 0.022a |

MDR: Multidrug resistance; PICU: Pediatric intensive care unit; EDR: Expanded drug resistance; GNI: Gram-negative infection; MV: Mechanical ventilation; PEG: Percutaneous endoscopic gastrostomy; PRISM: Pediatric risk of mortality score; *Chi-square test; *Fisher’s exact test; *Mann-Whitney U test
The use of invasive medical devices and surgical interventions increases the risk of HAI. The most common HAI include VAP, catheter-associated BSIs, UTIs, and BSIs (11). Similarly, the most common infections included VAP and BSI in our study. Catheter-associated UTI was found with a rate that was far below the rates reported previously (12). This may be related with the greater use of diapers and lower use of catheters due to low median age of our patients. The prevalence of VAP was found to be relatively high because most of our patients had chronic disease.

In a comprehensive study conducted by Eraksoy et al. (13) in which antimicrobial sensitivity was evaluated, the most
common resistant Gram-negative agents were \textit{E. coli}, \textit{K. pneumoniae}, \textit{P. aeruginosa}, and \textit{A. baumannii}. Although the rates are different in other studies, the most common agents are similar (14–16). In our study, the frequency of \textit{E. coli} was found to be markedly lower compared with the reported rates.

According to the 2007 Meropenem Yearly Susceptibility Test Information Collection (MYSTIC), the sensitivity of \textit{P. aeruginosa} isolates to piperacillin-tazobactam (PIP-TAZ) is considerably high in our country (13). However, PIP-TAZ resistance was found to be considerably high (72%) among \textit{P. aeruginosa} species in our study. Similarly, ceftazidime and meropenem resistances were also higher. This appears to be related to the fact that our patients were chronic patients, were being hospitalized for longer periods, and the rate of patients who received short-term postoperative care was very low because our clinic is a reference center. Due to these factors, our rates of empirical use of PIP-TAZ might have been high and our strategy to discontinue treatment in a short period might have been insufficient. In this context, it would not be appropriate to reflect our clinic’s resistance pattern to the whole country.

Treatment of resistant GNIs is especially difficult for pediatricians. Antibiotics including fluoroquinolone, colistin, and tigecycline are not used in pediatric patients except for obligatory conditions. In addition, Tigecycline, which is a rescuer for physicians caring for adults, has not been approved for use in children (17). During our follow-up, no significant adverse effects were observed in a 43-month-old patient with metabolic disease who was treated with a colistin-tigecycline combination and developed EDR, A. baumannii-associated VAP. This patient was treated successfully. Although it has been stated in a few publications related to use of tigecycline in children in the literature that it might be safe, further comprehensive studies are needed (18, 19). Similarly, one should also avoid empirical colistin treatment in children because of its adverse effects. Although the rate of colistin resistance was low in our study, the mortality rate was found to be high in our patients who used colistin. Undoubtedly, these patients had multiple factors including the EDR agent and the presence of underlying chronic disease.

As the hospitalization time increases, exposure to invasive interventions and antimicrobial drugs prolongs. Similarly, the rates for hospitalization longer than 15 days, prolonged PICU stay, use of TPN, history of GNE, and use of broad-spectrum antibiotics were found to be high in patients with EDR-GNIs in our study, as expected. Therefore, narrow-spectrum agents should be preferred to prevent antibiotic resistance, especially in patients with prolonged ICU hospitalization. The antibiotic spectrum should be narrowed according to the culture results and treatment should be discontinued appropriately in the shortest time.

In conclusion, antibiotic management politics should be conducted dynamically in addition to precautions in order to decrease mortality and morbidity rates related to HAIs. Although this study is a retrospective study and involves a limited number of patients, it is valuable in that it reflects the PICU data in a university hospital. Further studies especially related to PICUs should be conducted throughout our country.

Acknowledgement: We thank the head of the Nosocomial Infection Control Committee Professor Haluk Eraksoy and committee members for the surveillance study they meticulously conducted in our hospital.

Ethics Committee Approval: Ethics committee approval was received for this study from the Ethics Committee of Istanbul Medical Faculty (2017/485).

Informed Consent: Informed consent was not obtained from patients due to the retrospective nature of the study.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept - G.A., M.K., M.S.; Design - G.A., M.K., M.S., Y.S.A.; Supervision - S.H.T., A.C., K.N., N.S., A.S.; Data Collection and/or Processing - G.A., M.K., M.S., Y.S.A., B.A.K.; Analysis and/or Interpretation - G.A., M.K., M.S., S.H.T., A.C., K.N., N.S., A.S.; Literature Review - G.A., M.K., M.S., Y.S.A.; Writing - G.A., M.K., M.S.; Critical Review - S.H.T., A.C., K.N., N.S., A.S.

Conflict of Interest: The authors have no conflicts of interest to declare.

Financial Disclosure: The authors declared that this study has received no financial support.

Teşekkür: Hastane Enfeksiyon Kontrol Komitesi Başkanı Prof. Dr. Haluk Eraksoy ve komite üyelerine hastanemizde titizlikle yürütüklendiği çalışması nedeniyle teşekkür ederiz.

Etik Kurul Onay: Bu çalışma için etik kurul onayı İstanbul Tip fakültesi Etik Kurulu’ndan alınmıştır (2017/485).

Hasta Onam: Çalışmanın geriye dönük olarak yapılması nedeni ile hasta onamı alınmadı.

Hakem Değerlendirmesi: Dış bağımız.

Yazar Katkıları: Fikir - G.A., M.K., M.S.; Tasarım - G.A., M.K., M.S., Y.S.A.; Denetleme - S.H.T., A.C., K.N., N.S., A.S.;
Veri Toplanması ve/veya İşlemesi - G.A., M.K., M.S., Y.S.A., B.A.K.; Analiz ve/veya Yorum - G.A., M.K., M.S., S.H.T., A.C., K.N., N.S., A.S.; Literatür Taraması - G.A., M.K., M.S., Y.S.A.; Yazılı Yazan - G.A., M.K., M.S.; Eleştirel İnceleme - S.H.T., A.C., K.N., N.S., A.S.

Çıkar Çatışması: Yazarlar çıkar çatışması bildirmemişlerdir.

Mali Destek: Yazarlar bu çalışma için finansal destek almadıklarını beyan etmiştir.

References
1. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302: 2323–9.
2. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992-April 2000, issued June 2000. Am J Infect Control 2000; 28: 429–48.
3. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1–12.
4. Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013; 34: 1–14.
5. Gaynes R, Edwards JR; National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005; 41: 848–54.
6. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36: 309–32.
7. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-First-Twenty-Fourth Informational Supplement. CLSI document M100-S21-S24. Wayne, PA: Clinical and Laboratory Standards Institute; 2011-2014; 152–20.
8. Alberti C, Brun-Buisson C, Burchardi H, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 2002; 28: 108–21.
9. Rosenthal VD, Maki DG, Salomao R, et al. Device-associated nosocomial infections in 55 intensive care units of 8 developing countries. Ann Intern Med 2006; 145: 582–91.
10. Leblebicioglu H, Erben N, Rosenthal VD, et al. International Nosocomial Infection Control Consortium (INICC) national report on device-associated infection rates in 19 cities of Turkey, data summary for 2003-2012. Ann Clin Microbiol Antimicrob 2014; 13: 51.
11. Peleg AY, Hooper DC. Hospital-acquired infections due to gram-negative bacteria. N Engl J Med 2010; 362: 1804–13.
12. Yokoe DS, Anderson DJ, Berenholtz SM, et al. A compendium of strategies to prevent healthcare-associated infections in acute care hospitals: 2014 updates. Infect Control Hosp Epidemiol 2014; 35: 967–77.
13. Eraksoy H, Basustaoglu A, Korten V, et al. Susceptibility of bacterial isolates from Turkey-a report from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program. J Chemother 2007; 19: 650–7.
14. İnci A, Güven D, Atasoy R. Microorganisms isolated from various clinical samples of intensive care unit patients and their antibiotic susceptibilities. J Clin Anal Med 2014; 5: 466–8.
15. Ok G, Gazi H, Tok D, et al. Surveillance of nosocomial infections in Celal Bayar University Anesthesiology Intensive Care Unit. J Int Care 2007; 7: 452–7.
16. Ece G, Adanır T. The Evaluation of the Distribution and Antimicrobial Susceptibility Profile of the Strains Isolated at Anesthesiology Intensive Care Unit. Journal of Clinical and Analytical Medicine 2014; 5: 320–3.
17. Purdy J, Jouve S, Yan JL, et al. Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. Clin Ther 2012; 34: 496–507.e1.
18. Iosifidis E, Violaki A, Michalopoulou E, et al. Use of Tigecycline in Pediatric Patients With Infections Predominantly Due to Extensively Drug-Resistant Gram-Negative Bacteria. J Pediatric Infect Dis Soc 2017; 6: 123–8.
19. Mastrolia MV, Galli L, De Martino M, Chiappini E. Use of tigecycline in pediatric clinical practice. Expert Rev Anti Infect Ther 2017; 15: 605–12.